Capstar Special Purpose Acquisition Corp. (CPSR) Re-Strikes Gelesis Deal

Capstar (NYSE:CPSR) announced in an 8-K this morning that it is revising its combination agreement with biopharm firm Gelesis in the latest deal to be re-struck on more investor-friendly terms. The changes slash Gelesis’ proposed equity valuation by 25% from $900 million to $675 million in exchange for concessions on earnout shares and the sponsor’s
Read More